CASI News and Press, CASI Pharmaceuticals Inc. From 02/16/24

CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA PR Newswire BEIJING , Feb. 16, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative th...

2024-02-05 06:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-25 18:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-27 10:50:10 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom September Labor Report Preview: Full Employ...

2023-11-14 07:34:54 ET More on CASI Pharmaceuticals Seeking Alpha’s Quant Rating on CASI Pharmaceuticals Historical earnings data for CASI Pharmaceuticals Financial information for CASI Pharmaceuticals For further details see: CASI Pharmaceuticals ...

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES PR Newswire BEIJING , Nov. 14, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative t...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

CASI Pharmaceuticals Inc. (CASI) is expected to report $-0.56 for Q3 2023

CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA PR Newswire BEIJING , Nov. 8, 2023 /PRNewswire/ -- CASI Pharmaceuticals Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and p...

2023-08-11 07:45:03 ET CASI Pharmaceuticals press release ( NASDAQ: CASI ): Q2 GAAP EPS of -$0.77. Revenue of $9.82M (+14.6% Y/Y). As of June 30, 2023, CASI had cash, cash equivalents and short-term investments of $36.8 million. For further details see: CASI ...